Event Abstract

Back to Event

TUMOR VACCINE FOR ORAL CANCER: PROSPECTS AND CHALLENGES IN DENTISTRY

Gabriel S. Rodrigues1*
  • 1 Kasturba Medical College, Manipal University, Manipal, General Surgery, India

Oral cancer is one of the major reasons for morbidity and mortality worldwide. Despite significant advances in radiation, surgery and chemotherapy, substantial gap remains in its effective control. Even with all recent advances, the overall five-year survival rate for oral cancer has remained status quo at around 55% and hence, a need for effective vaccine has been felt for long that could confer long-term immunity and have a huge impact in control of this deadly disease. We did a retrospective literature search with key terms “Tumors Vaccines” AND “Oral Cancers” AND “Dentistry” through Pub Med, MEDSCAPE, MICROMEDEX, relevant immunology, dental and medicine journals and this was done independently by the authors. Majority of tumor vaccine research in dentistry is limited to Human Papilloma Virus (HPV) vaccines. However these are more focused on cervical cancer, with oral malignancy as only one of the secondary outcomes. It has been observed that HPV has a definitive role in oral cancers and these vaccines could have a positive impact in prevention of its ever-increasing incidence, though gray areas in research like optimal dosing schedule, efficacy in men, duration of protection and oral cancer specific studies remain unanswered. Emergence of second generation tumor vaccines against oral cancer does seem promising. There is a need to sensitize dental professionals with the latest advancement in tumor vaccines. A subtle shift from bench side research to bed side availability of an effective tumor vaccine in dentistry armamentarium does not seem to be a distant dream.

References

1. Das BR, Nagpal KJ. Understanding the biology of oral cancer. Med Sci Monit 2002;8:RA258-67.
2. Parkin DM, Bray F. Chapter 2: The burden of HPV related cancers. Vaccine 2006;24 Suppl 3:S11-25.
3. Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB. Cancer incidence in five continents. Vol 8. Lyon: IARC Scientific Publications, 2002.
4. Herrero R, Castellsague X, Pawlita M, Lissowska J, Kee F, Balaram P, et al. Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst 2003;95:1772–83.
5. Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 2005;14:467–75.
6. Sussman AL, Helitzer D, Sanders M, Urquieta B, Salvador M, Ndiaye K. HPV and cervical cancer prevention counseling with younger adolescents: implications for primary care. Ann Fam Med 2007;5:298-304.
7. Lea JS, Sunaga N, Sato M, Kalahasti G, Miller DS, Minna JD, et al. Silencing of HPV 18 oncoproteins with RNA interference causes growth inhibition of cervical cancer cells. Reprod Sci 2007;14:20-8.
8. Wright TC, Bosch FX, Franco EL, Cuzick J, Schiller JT, Garnett GP, et al. Chapter 30: HPV vaccines and screening in the prevention of cervical cancer: conclusions from a 2006 workshop of international experts. Vaccine 2006;24 Suppl 3:S251-261.
9. MICROMEDEX ® Healthcare Series, Thompson Micromedex, Greenwood Villange, Colorado. Vol.133 expires 9/2010.
10. Quadrivalent Human Papillomavirus Vaccine. Recommendations of the advisory committee on immunization practices – March 12, 2007. ‘http://www.cdc.gov/mmwr/preview/mmwrhtml/rr56e312a1.htm’. Accessed April 2010.
11. Marais DJ, Sampson C, Jeftha A, Dhaya D, Passmore JA, Denny L, et al. More men than women make mucosal IgA antibodies to Human papillomavirus type 16 (HPV-16) and HPV-18: a study of oral HPV and oral HPV antibodies in a normal healthy population. BMC Infect Dis 2006;6:95.
12. Agarwal A, Mohanti BK, Das SN. Ex vivo triggering of T-cell-mediated immune responses by autologous tumor cell vaccine in oral cancer patients. Immunopharmacol Immunotoxicol 2007;29:95-104.
13. Maeda H, Kubo K, Sugita Y, Miyamoto Y, Komatsu S, Takeuchi S, et al. DNA vaccine against hamster oral papillomavirus-associated oral cancer. J Int Med Res 2005;33:647-53.
14. Palefsky JM. HPV infection in men. Dis Markers 2007;23:261-72.
15. Lajiness MJ. The new vaccine to prevent HPV. Urol Nurs 2007;27:153-4.
16. Zur Hausen H. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst 2000;92:690-8.
17. Franco EL, Bosch XF, Cuzick J, et al. Chapter 29: Knowledge, gaps and priorities for research on prevention of HPV infection and cervical cancer. Vaccine 2006;24 Suppl 3:S242-9.
18. Wood D, Shin J, Duval B, Schmitt HJ. Chapter 22: Assuring the quality, safety, efficacy of HPV vaccines: The scientific basis of regulatory expectations pre- and post-licensure. Vaccine 2006;24 Suppl 3:S187-92.
19. Shinn DL. Fear and anxiety. Br Dent J 2007;202:2.
20. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomized control trial. Lancet 2006; 367:1247–55.

Keywords: tumor, Vaccine, Human Papilloma Virus, oral cancer, excision

Conference: 15th International Congress of Immunology (ICI), Milan, Italy, 22 Aug - 27 Aug, 2013.

Presentation Type: Abstract

Topic: Immune-mediated disease pathogenesis

Citation: Rodrigues GS (2013). TUMOR VACCINE FOR ORAL CANCER: PROSPECTS AND CHALLENGES IN DENTISTRY. Front. Immunol. Conference Abstract: 15th International Congress of Immunology (ICI). doi: 10.3389/conf.fimmu.2013.02.00773

Copyright: The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers. They are made available through the Frontiers publishing platform as a service to conference organizers and presenters.

The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated.

Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed.

For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions.

Received: 17 Jun 2013; Published Online: 22 Aug 2013.

* Correspondence: Prof. Gabriel S Rodrigues, Kasturba Medical College, Manipal University, Manipal, General Surgery, Manipal, India, rodricksgaby@yahoo.co.in